Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer.

By Ana Costa, Y. Kieffer, A. Scholer-Dahirel, Floriane Pelon, B. Bourachot, M. Cardon, P. Sirven, Ilaria Magagna, L. Fuhrmann, Charles Bernard and 9 more. Cancer Cell, 2018

1,448 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/4d1f4dfc8cb1bf3a8b92c5a21bfe18003453769d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. A. Labani-Motlagh
2. Mehrnoush Ashja-Mahdavi
3. A. Loskog

In Oncology

1. Giulia Biffi
2. D. Tuveson
3. Ela Elyada
4. Rakesh K. Jain

Citations in the corpus

• The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses (2020, background): “In the TME, MDSCs are activated by various molecular factors such as VEGF, GM-CSF, C5a, MMP9, IFN-γ, TGF-β, IL-1β, IL-6, IL-10, IL-12, IL-13, CCL2, CXCL5, CXCL12, gangliosides, and prostaglandins (111).”
• Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments (2023, background): “It’s worth to further explore the relationship between Treg and CAFs in various cancers.”
• Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. (2020, methodology): “Immunosuppressive environment Correlates with Specific CAF-S1 Clusters As we showed that CAF-S1 fibroblasts exert immunosuppression in breast and ovarian cancers (8, 10), we next investigated whether this function could be exerted by all CAF-S1 clusters or restricted to specific ones (Fig.”
• Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer (2021, methodology): “Recently, single-cell RNA-sequencing and conventional RNA-sequencing of human tissues have allowed better unbiased assessment of heterogeneous CAFs.(20,58,59) By analyzing a combination of classical markers, such as FAP and PDGFRβ, CAFs in breast cancer were distinguished by levels of marker express”
• Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives (2021, background): “Breast cancer CAF-S1 CD29, FAP, α-SMA, PDGFRβ, FSP1 and CXCL12 Tumor proliferation, Migration, Lymph-nodes metastasis, Immune suppression and EMT initiation [96, 98]”
• Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma (2020, background): “Interestingly, CD276 (B7-H3), known to augment Tregs and inhibit T cell responses (Costa et al., 2018; Prasad et al., 2004; Suh et al., 2003), was expressed most prominently on CAFs and TSKs.”